Zacks: Analysts Anticipate Ocular Therapeutix, Inc. (NASDAQ:OCUL) Will Post Earnings of -$0.22 Per Share

Analysts expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Ocular Therapeutix’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.28). Ocular Therapeutix posted earnings of ($0.17) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 29.4%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Ocular Therapeutix will report full-year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.68) to ($0.48). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.95) to $0.39. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, August 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.09. Ocular Therapeutix had a negative net margin of 318.77% and a negative return on equity of 51.58%.

Several research firms recently weighed in on OCUL. HC Wainwright upgraded shares of Ocular Therapeutix from a “neutral” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Tuesday, August 10th. Zacks Investment Research cut shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Wednesday, August 11th. Piper Sandler reiterated a “buy” rating and set a $28.00 price target on shares of Ocular Therapeutix in a research report on Friday, July 23rd. Finally, JMP Securities increased their price target on shares of Ocular Therapeutix to $33.00 and gave the company a “market outperform” rating in a research report on Thursday, September 9th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $23.67.

In related news, CEO Antony C. Mattessich acquired 5,000 shares of the company’s stock in a transaction dated Friday, August 20th. The stock was purchased at an average price of $9.89 per share, with a total value of $49,450.00. Following the completion of the purchase, the chief executive officer now owns 102,900 shares in the company, valued at approximately $1,017,681. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 3.60% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Centerpoint Advisors LLC boosted its stake in shares of Ocular Therapeutix by 91.2% during the second quarter. Centerpoint Advisors LLC now owns 2,390 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,140 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Ocular Therapeutix by 203.2% during the second quarter. Macquarie Group Ltd. now owns 3,590 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 2,406 shares during the period. Shell Asset Management Co. purchased a new stake in shares of Ocular Therapeutix during the first quarter valued at approximately $119,000. Lindbrook Capital LLC boosted its stake in shares of Ocular Therapeutix by 13.9% during the second quarter. Lindbrook Capital LLC now owns 8,200 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,000 shares during the period. Finally, JS Capital Management LLC purchased a new stake in shares of Ocular Therapeutix during the first quarter valued at approximately $172,000. 63.02% of the stock is owned by hedge funds and other institutional investors.

Shares of OCUL stock traded down $0.16 during trading on Friday, hitting $10.54. The company had a trading volume of 6,878 shares, compared to its average volume of 942,638. The company has a quick ratio of 10.00, a current ratio of 10.05 and a debt-to-equity ratio of 0.63. The stock’s 50-day moving average is $11.27 and its two-hundred day moving average is $14.35. The stock has a market capitalization of $807.18 million, a price-to-earnings ratio of -5.60 and a beta of 2.14. Ocular Therapeutix has a 52 week low of $7.50 and a 52 week high of $24.30.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

See Also: What is the QQQ ETF?

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.